We are currently in closed period. Normal Investor Relations meetings and activities will resume from 17 September 2018 following the release of our FY2018 Annual Results.
We are well positioned in both developing and developed markets. As the largest pharmaceutical company in Africa, we have an expanding presence in Latin America, Asia, Europe and the Commonwealth of Independent States, comprising Russia and the former Soviet Republics (“CIS”). We are also one of the leading pharmaceutical companies in Australia and are establishing a presence in other developed markets such as the United States of America (“USA”) and Canada.
With an extensive basket of products that provide treatment for a broad spectrum of acute and chronic conditions experienced throughout all stages of life, we continue to increase the number of lives benefiting from our products, reaching more than 150 countries across the world.
Our results for the six months ended 31 December 2017 will be announced at a presentation and webcast on Friday, 9 March 2018.
The presentation will be available for download here and on the home page of this website from 9 March 2018.
Strong market position
Diversified geographies and product offering
Proven track record
Leverages on local knowledge and expertise
Centralised Group activities facilitate synergies and mitigate pricing pressures
Positive growth drivers
Responsible corporate citizen
8 March 2018
Interim results announcement
9 March 2018
Interim results presentation in Cape Town
30 June 2018
Financial year end
13 September 2018
Year end results announcement, presentation and webcast at the JSE, Johannesburg
Publishing of the Integrated Report
6 December 2018
Annual General Meeting
SHARE PRICE CENTRE
View share price information for Aspen Holdings.
APN ISIN: ZAE 000066692
JSE data delayed by 15 minutes, page refreshes every 5 minutes. Indicated trade times are actual.
Delivering double-digit earnings growth to our shareholders for 17 consecutive years
Analysis of shareholders at 30 June 2016
All corporate information and contact details